Full Breakdown
Promising Advances in Prostate Cancer Treatment: VIR-5500 and 225Ac-PSMA-Trillium
2/28/2026, 8:50:04 PM
Breakthroughs in Immunotherapy for Prostate Cancer
Recent clinical trials have unveiled promising results for two innovative treatments targeting advanced prostate cancer: the immunotherapy drug VIR-5500 and the targeted radiotherapy 225Ac-PSMA-Trillium. Prostate cancer remains the most common cancer among men globally, with approximately 1.5 million diagnoses each year. These new therapies aim to address the urgent need for effective treatments, particularly for patients who have exhausted other options.
VIR-5500: A New Immunotherapy Approach
VIR-5500, an engineered antibody designed to engage the body’s immune system, has shown significant potential in early-stage trials. Conducted by Professor Johann de Bono at the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, the phase one trial involved 58 men with advanced prostate cancer who had not responded to previous treatments. The results indicated that 82% of patients experienced a reduction in prostate-specific antigen (PSA) levels, a key biomarker for prostate cancer, with 53% achieving a drop of at least 90%. Notably, 88% of participants reported only mild side effects, a significant improvement over traditional immunotherapies.
De Bono described the results as unprecedented for a disease previously considered resistant to immunotherapy. The drug's unique mechanism, which activates only within tumor cells, minimizes adverse reactions and allows for fewer doses. This innovative approach has led to tumor shrinkage in several patients, including a case where 14 liver lesions completely resolved after treatment.
225Ac-PSMA-Trillium: Targeted Radiotherapy
In a parallel development, the 225Ac-PSMA-Trillium treatment employs a targeted radiotherapy approach that has demonstrated remarkable efficacy. This phase one trial, also led by Professor de Bono, involved 50 participants with PSMA-positive advanced prostate cancer. Results showed that 83% of patients had stable disease, with nearly half experiencing tumor shrinkage. The treatment utilizes a "homing device" to deliver radiation directly to cancer cells, significantly reducing damage to surrounding healthy tissue.
The trial's findings were presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, where experts expressed optimism about the potential of this targeted approach. Professor Kristian Helin, chief executive of the Institute of Cancer Research, emphasized the importance of overcoming treatment resistance in cancer therapy.
Expert Perspectives and Future Directions
Experts in the field have welcomed these advancements. Charlotte Bevan, a professor of cancer biology at Imperial College London, highlighted the need for further studies involving diverse patient populations to ensure equitable treatment outcomes. Simon Grieveson, assistant director of research at Prostate Cancer UK, echoed the sentiment, noting the urgency for innovative therapies given the high mortality rate associated with prostate cancer.
Both treatments are set to progress into larger clinical trials to validate their efficacy and safety further. As Professor de Bono stated, “There is certainly hope that drugs such as this will increase the likelihood of a cure even from advanced prostate cancer.”
Verbatim Quotes
- “We believe that such treatments may in the long term lead to cures,” — Prof Johann de Bono, Institute of Cancer Research
- “Pending further clinical validation, available data are suggestive of a generally favourable safety profile, with evidence of meaningful anti-tumour activity,” — ASCO Abstract
- “Once prostate cancer stops responding to hormone therapies, treatment options are really limited for patients. If 225Ac-PSMA-Trillium provides benefit to patients in larger trials, the drug could offer fresh hope to patients who urgently need more effective treatments.” — Prof Johann de Bono, Institute of Cancer Research
These developments mark a significant step forward in the fight against prostate cancer, offering renewed hope for patients and their families.
